Fig. 4 | Hypertension Research

Fig. 4

From: Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers

Fig. 4

Urinary Sodium and Potassium Concentrations Following Baxdrostat Administration. Urine sodium and potassium concentrations at baseline (BL), day 1, and day 10. Box whiskers show interquartile range (box) and minimum-maximum (whiskers) for sodium or potassium from 24 h urine collections

Back to article page